个人简介
温州医科大学学士、浙江大学临床检验诊断学硕士；主要从事临床免疫学检测工作，擅长免疫学检测易干扰项目的分析及纠正。主持或参与浙江省自然基金二项，第一作者发表SCI论文4篇。
专业擅长
乙肝及肿瘤标志物易干扰项目的鉴别和纠正
研究方向
乙肝免疫临床及基础研究
成果奖项：（近五年主要成果及奖励情况）
(1) Ma Guanghua; Lou Bin; Lv Feifei; Zhao Dejian; Zhang Zhe; Chen Yu ; HBcrAg and pg RNA and the therapeutic effect in HBeAg-positive patients receiving anti-viral therapy, baseline serumHBV-RNA is a powerful predictor of response., Journal of viral hepatitis, 2020, 27(8): 837-846
(2) Ma Guanghua; Lou Bin; Lv Feifei; Zhao Dejian; Chen Hui; Ye Xianfei; Chen Yu; HBcrAg, pgRNA and HBsAg dynamically supervise the seroconversion of HBsAg with anti-viral therapy: "Loss of HBsAg" maybe not a good end-point of anti-viral therapy., Clinica Chimica Acta, 2020,10(049)
(3) Lou bin; Ma guanghua; Lv feifei; Yuan quan; Xu fanjie; Dong yuejiao; Lin sha; Tan yajun; Zhang jie; Chen yu ; Baseline Quantitative Hepatitis B Core Antibody Titer Is a Predictor for Hepatitis B Virus Infection Recurrence After Orthotopic Liver Transplantation., Frontiers inImmunology, 2021, 12(710528)
(4) Lou bin; Ma guanghua; Xiaopeng Yu;Lv feifei;Deubiquitinase OTUD5 promotes hepatitis B virus replication by removing K48-linked ubiquitination of HBV core/precore and upregulates HNF4ɑ expressions by inhibiting the ERK1/2/mitogen-activated protein kinase pathway.Cell Mol Life Sci 2023 Oct 28;80(11)
课题：
(1) 浙江省自然科学基金委员会, 分析测试, TGC23H100001, 基于多代谢谱的自身免疫性肝病临床精确诊断及预。 后评估方法研究，参与
(2) 浙江省自然科学基金委员会, 探索公益, TGY23H200020, HBx通过E3连接酶RNF126抑制JAK-STAT信号通路促进乙肝的复制增殖的机制及临床应用研究。主持
社会任职
无
